Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Atsunori KashiwagiShingo ShojiSatoshi OnozawaYoshinori KosakaiMiina WarataniYuichiro ItoPublished in: Journal of diabetes investigation (2022)
In this real-world study, SGLT2i versus DPP4i was associated with a significant reduction in hHF, ACD and hHF or ACD events in patients with type 2 diabetes mellitus without a CVD history.